Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall discussions reflect a strong focus on the safety and efficacy of norepinephrine versus epinephrine, as evidenced by comments like 'norepinephrine is probably preferred' and mentions of trials showing its potential superiority. The tone integrates clinical observations and research findings, demonstrating both interest and a recognition of the study's relevance for future treatment standards.
Most discussions agree that norepinephrine might be preferable to epinephrine in cardiogenic shock, with some referencing studies and clinical experience supporting that view.
Posts show high interest by referencing multiple trials and discussing the implications of the findings for clinical practice.
Participants actively analyze the study's details, mentioning side effects, existing evidence, and practical considerations, indicating moderate engagement.
The discussions suggest the research could influence treatment decisions, especially as several posts question and compare vasopressor choices, highlighting a potential shift in clinical approaches.
Interesting. Seems like data tilting toward norepinephrine in post arrest and early cardiogenic (https://t.co/n3welLOgAK) shock. Worry a bit about confounding by indication, but seems reasonable to pick norepi first for now. https://t.co/X2ridPH7zT
Acute MI and cardiogenic shock n=57: *(Dobutamine in 67% of both groups) -Adrenaline: ↑ heart rate, lactic acidosis, refractory shock. -Noradrenaline: = heart rate, earlier lactate clearance. -Similar SvO2 / ΔPCO2. Vasopressor of choice? https://t.co/CFTuKwP1Fd @JACCJournals https://t.co/RxHYzvYlq5
@IM_Crit_ In cardiogenic shock epinephrine is bad news tho (⬆️ refractory shock in AMI CS https://t.co/0oxyxbDfRq). When in doubt, levophed haha
In cardiogenic shock after #AMI evidences for norephinephrine and early revascularization of culprit vessels. @iccvanderhorst 1. https://t.co/bUnLcIIrLR 2. https://t.co/qNFCNrxvw9 @ESICM #LIVES2019 #FOAMed #FOAMcc https://t.co/8Lkwf1q1aZ
@OneArmWonder @CatherineCounts @EmmaWender @SayreMR @SeattleFire @uwmnewsroom @UWashEM @mollyvandyke This is not a study of push-dose vasoactives. And distributive shock is incredibly common following ROSC and a key feature of the post-arrest syndrome. AND norepinephrine is probably preferred as first-line for cardiogenic shock. https://t.co/n3welLOgAK
This video discusses the safety of using norepinephrine infusions through peripheral IV lines during surgery. With a review of 14,385 patients, the study suggests a very low risk of complications, significantly aiding…
This video explores the efficacy of norepinephrine versus epinephrine as vasopressors in managing cardiogenic shock. We discuss recent findings and clinical guidelines to determine which medication may improve patient…
The Café com Journal series delivers a weekly update on recent cardiology publications. In today's session, we discuss original articles from JACC, BMJ, and Circulation, highlighting key findings and new guidelines…
@OneArmWonder @CatherineCounts @EmmaWender @SayreMR @SeattleFire @uwmnewsroom @UWashEM @mollyvandyke This is not a study of push-dose vasoactives. And distributive shock is incredibly common following ROSC and a key feature of the post-arrest syndrome. AND norepinephrine is probably preferred as first-line for cardiogenic shock. https://t.co/n3welLOgAK
RT @PharmacyToDose: #TrialOfTheDay for July 10th is the OptimaCC trial A study challenging the status quo vasopressor treatment in cardiog…
RT @PharmacyToDose: #TrialOfTheDay for July 10th is the OptimaCC trial A study challenging the status quo vasopressor treatment in cardiog…
#TrialOfTheDay for July 10th is the OptimaCC trial A study challenging the status quo vasopressor treatment in cardiogenic shock Open-access article link: https://t.co/PS5hh3wNRk #pharmicu #pharmem #emrx #twitterx #foamed #foamcc #cardiotwitter #cardiogenicshock #vasopressor https://t.co/WOpXBybinc
#TrialOfTheDay for July 10th is the OptimaCC trial A study challenging the status quo vasopressor treatment in cariogenic shock Open-access article link: https://t.co/PS5hh3wNRk #pharmicu #pharmem #emrx #twitterx #foamed #foamcc #cardiotwitter #cardiogenicshock #vasopressor https://t.co/N2R4cCOpIT
@plastic_baggy17 @Q2turnQueen In this study patients had a mean of 0.6 and 0.7 mcg/kg/min of NE/EPI https://t.co/TQpsECbxDe. When researching this paper I encountered many trials that exceeded what it seems some institutions might consider "high" https://t.co/5Tv2FXUMVo
@MattStier_PSTP @YukiKotani5 Agree re VANISH & VASO. I agree that theoretically epi could have more arrhythmias. It’s true that the absence of evidence isn’t always reassuring, and Epi’s clearly got more side effects vs NE in the trials we have (not necessarily more arrhythmias tho). https://t.co/YoJD5TgFCz
@airambulancedoc @CRM_saves_lives @red_capDE @Moeritzl @Nell781 @schnudelmann https://t.co/kLiJb4ni5b https://t.co/nQ4NelxNgN In der LL Infarktbedingter Schock als "kann", wenn NA und Dobu keine ausreichende Stabilisierung - klingt für mich eher als Ultima ratio.
RT @LeivaOrly: @IM_Crit_ In cardiogenic shock epinephrine is bad news tho (⬆️ refractory shock in AMI CS https://t.co/0oxyxbDfRq). When in…
RT @LeivaOrly: @IM_Crit_ In cardiogenic shock epinephrine is bad news tho (⬆️ refractory shock in AMI CS https://t.co/0oxyxbDfRq). When in…
RT @LeivaOrly: @IM_Crit_ In cardiogenic shock epinephrine is bad news tho (⬆️ refractory shock in AMI CS https://t.co/0oxyxbDfRq). When in…
@IM_Crit_ In cardiogenic shock epinephrine is bad news tho (⬆️ refractory shock in AMI CS https://t.co/0oxyxbDfRq). When in doubt, levophed haha
@PharmD_intheED Also this https://t.co/pAIx6Jflj4
RT @NickJohnsonMD: Interesting. Seems like data tilting toward norepinephrine in post arrest and early cardiogenic (https://t.co/n3welLOgAK…
RT @NickJohnsonMD: Interesting. Seems like data tilting toward norepinephrine in post arrest and early cardiogenic (https://t.co/n3welLOgAK…
@pedrodammert @CarlbomMD Agreed. Some randomized trial data in an adjacent population (https://t.co/n3welM5jCK), but agree that needs to be studied prospectively in post-arrest patients.
RT @NickJohnsonMD: Interesting. Seems like data tilting toward norepinephrine in post arrest and early cardiogenic (https://t.co/n3welLOgAK…
RT @NickJohnsonMD: Interesting. Seems like data tilting toward norepinephrine in post arrest and early cardiogenic (https://t.co/n3welLOgAK…
RT @NickJohnsonMD: Interesting. Seems like data tilting toward norepinephrine in post arrest and early cardiogenic (https://t.co/n3welLOgAK…
RT @NickJohnsonMD: Interesting. Seems like data tilting toward norepinephrine in post arrest and early cardiogenic (https://t.co/n3welLOgAK…
RT @NickJohnsonMD: Interesting. Seems like data tilting toward norepinephrine in post arrest and early cardiogenic (https://t.co/n3welLOgAK…
RT @NickJohnsonMD: Interesting. Seems like data tilting toward norepinephrine in post arrest and early cardiogenic (https://t.co/n3welLOgAK…
RT @NickJohnsonMD: Interesting. Seems like data tilting toward norepinephrine in post arrest and early cardiogenic (https://t.co/n3welLOgAK…
@MercadalJordi @luigizattera @yourICM @Dr_Cit @nickmmark @FOAMecmo @LionelLamhaut @JoeTonnaMD @EM_RESUS @stlegriel @jas_soar @DrMCecconi Perhaps, but we also have randomized data in cardiogenic shock due to ACS still suggesting that norepi is at least as good if not superior: https://t.co/n3welM5jCK
RT @NickJohnsonMD: Interesting. Seems like data tilting toward norepinephrine in post arrest and early cardiogenic (https://t.co/n3welLOgAK…
RT @NickJohnsonMD: Interesting. Seems like data tilting toward norepinephrine in post arrest and early cardiogenic (https://t.co/n3welLOgAK…
RT @NickJohnsonMD: Interesting. Seems like data tilting toward norepinephrine in post arrest and early cardiogenic (https://t.co/n3welLOgAK…
RT @NickJohnsonMD: Interesting. Seems like data tilting toward norepinephrine in post arrest and early cardiogenic (https://t.co/n3welLOgAK…
RT @NickJohnsonMD: Interesting. Seems like data tilting toward norepinephrine in post arrest and early cardiogenic (https://t.co/n3welLOgAK…
Interesting. Seems like data tilting toward norepinephrine in post arrest and early cardiogenic (https://t.co/n3welLOgAK) shock. Worry a bit about confounding by indication, but seems reasonable to pick norepi first for now. https://t.co/X2ridPH7zT
@fabio_taccone @yourICM @DrMCecconi @Dr_Cit @FOAMecmo @msh_manu @ElieAzoulay5 @Manu_Malbrain @criticcaredoc @AlhazzaniW @iwashyna 2018 study showing norepi May be better in Acute MI associated cardiogenic shock. https://t.co/KjFaAgZ6sW
(ALSO bonus tweet not a fan of DA or EPI in CS d/t limited data showing potentially worse outcomes like pro arrhythmic data w/ DA in CS https://t.co/U4jo9YdGD2, and potentially worse outcome w/ EPI in ischemic CS https://t.co/VpDqeBqh1Q). NE +Dobut for life! #Medtwitter
RT @diglalv: Acute MI and cardiogenic shock n=57: *(Dobutamine in 67% of both groups) -Adrenaline: ↑ heart rate, lactic acidosis, refractor…
RT @diglalv: Acute MI and cardiogenic shock n=57: *(Dobutamine in 67% of both groups) -Adrenaline: ↑ heart rate, lactic acidosis, refractor…
Acute MI and cardiogenic shock n=57: *(Dobutamine in 67% of both groups) -Adrenaline: ↑ heart rate, lactic acidosis, refractory shock. -Noradrenaline: = heart rate, earlier lactate clearance. -Similar SvO2 / ΔPCO2. Vasopressor of choice? https://t.co/CFTuKwP1Fd @JACCJournals https://t.co/RxHYzvYlq5
#Adrenalina vs #norepinefrina en choque cardiogénico post #IAM https://t.co/XlxNXKTliE https://t.co/imJZImuZ8M
RT @EMPoisonPharmD: Based on data EPI seems reasonable in normal heart/distributive shocks. EPI data in CS scant at best, but available dat…
Based on data EPI seems reasonable in normal heart/distributive shocks. EPI data in CS scant at best, but available data signals concern that warrants further exploration (https://t.co/rKhcq8Y8TS , https://t.co/xX5hatMojD) #FOAMcc 3/6
RT @tscquizzato: In cardiogenic shock after #AMI evidences for norephinephrine and early revascularization of culprit vessels. @iccvanderho…
RT @tscquizzato: In cardiogenic shock after #AMI evidences for norephinephrine and early revascularization of culprit vessels. @iccvanderho…
RT @tscquizzato: In cardiogenic shock after #AMI evidences for norephinephrine and early revascularization of culprit vessels. @iccvanderho…
RT @tscquizzato: In cardiogenic shock after #AMI evidences for norephinephrine and early revascularization of culprit vessels. @iccvanderho…
RT @tscquizzato: In cardiogenic shock after #AMI evidences for norephinephrine and early revascularization of culprit vessels. @iccvanderho…
RT @tscquizzato: In cardiogenic shock after #AMI evidences for norephinephrine and early revascularization of culprit vessels. @iccvanderho…
RT @tscquizzato: In cardiogenic shock after #AMI evidences for norephinephrine and early revascularization of culprit vessels. @iccvanderho…
RT @tscquizzato: In cardiogenic shock after #AMI evidences for norephinephrine and early revascularization of culprit vessels. @iccvanderho…
In cardiogenic shock after #AMI evidences for norephinephrine and early revascularization of culprit vessels. @iccvanderhorst 1. https://t.co/bUnLcIIrLR 2. https://t.co/qNFCNrxvw9 @ESICM #LIVES2019 #FOAMed #FOAMcc https://t.co/8Lkwf1q1aZ
@fluidloading @Rhazelovitch @Brain_Juice Et reoooooohhhhhhh Interesting article "Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction" (via #pubmedontap) https://t.co/paLQF0hvon
RT @La_SRLF:
RT @La_SRLF:
RT @La_SRLF:
Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction. - PubMed - NCBI https://t.co/ieK96kckyT